Cargando…

CCR5 Inhibitors and HIV-1 Infection

Detalles Bibliográficos
Autores principales:	Latinovic, Olga S., Reitz, Marvin, Heredia, Alonso
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6693856/ https://www.ncbi.nlm.nih.gov/pubmed/31414081 http://dx.doi.org/10.33696/AIDS.1.001

Ejemplares similares

Identifying CCR5 coreceptor populations permissive for HIV-1 entry and productive infection: implications for in vivo studies
por: Weichseldorfer, Matthew, et al.
Publicado: (2022)

Use of Humanized Mouse Models for Studying HIV-1 Infection, Pathogenesis and Persistence
por: Weichseldorfer, Matthew, et al.
Publicado: (2020)

Past HIV-1 Medications and the Current Status of Combined Antiretroviral Therapy Options for HIV-1 Patients
por: Weichseldorfer, Matthew, et al.
Publicado: (2021)

A novel small-molecule inhibitor of HIV-1 entry
por: Heredia, Alonso, et al.
Publicado: (2015)

Combined cART including Tenofovir Disoproxil, Emtricitabine, and Dolutegravir has potent therapeutic effects in HIV-1 infected humanized mice
por: Weichseldorfer, Matthew, et al.
Publicado: (2021)

Clinical use of CCR5 inhibitors in HIV and beyond
por: Gilliam, Bruce L, et al.
Publicado: (2011)

Two HIV-1 Variants Resistant to Small Molecule CCR5 Inhibitors Differ in How They Use CCR5 for Entry
por: Berro, Reem, et al.
Publicado: (2009)

Targeting CCR5 trafficking to inhibit HIV-1 infection
por: Boncompain, Gaelle, et al.
Publicado: (2019)

CCR5 inhibitors: Emerging promising HIV therapeutic strategy
por: Rao, Padmasri Kutikuppala Surya
Publicado: (2009)

Beyond HIV infection: Neglected and varied impacts of CCR5 and CCR5Δ32 on viral diseases
por: Ellwanger, Joel Henrique, et al.
Publicado: (2020)

Maraviroc – A CCR5 Antagonist for the Treatment of HIV-1 Infection
por: Van Der Ryst, Elna
Publicado: (2015)

Accelerated Immunodeficiency by Anti-CCR5 Treatment in HIV Infection
por: Weinberger, Ariel D., et al.
Publicado: (2009)

Association of chemokine receptor gene (CCR2-CCR5) haplotypes with acquisition and control of HIV-1 infection in Zambians
por: Malhotra, Rakhi, et al.
Publicado: (2011)

CCR5Δ32 Genotypes in a German HIV-1 Seroconverter Cohort and Report of HIV-1 Infection in a CCR5Δ32 Homozygous Individual
por: Oh, Djin-Ye, et al.
Publicado: (2008)

Natural anti-CCR5 antibodies in HIV-infection and -exposure
por: Lopalco, Lucia
Publicado: (2011)

CCR5 and HIV Infection, a View from Brussels
por: Parmentier, Marc
Publicado: (2015)

The Effects of the Recombinant CCR5 T4 Lysozyme Fusion Protein on HIV-1 Infection
por: Jin, Qingwen, et al.
Publicado: (2015)

Stochastic Model of In-Vivo X4 Emergence during HIV Infection: Implications for the CCR5 Inhibitor Maraviroc
por: Savkovic, Borislav, et al.
Publicado: (2012)

Inhibition of Dual/Mixed Tropic HIV-1 Isolates by CCR5-Inhibitors in Primary Lymphocytes and Macrophages
por: Surdo, Matteo, et al.
Publicado: (2013)

CCR5AS lncRNA variation differentially regulates CCR5, influencing HIV disease outcome
por: Kulkarni, Smita, et al.
Publicado: (2019)

Endocytosis and Recycling of the HIV Coreceptor Ccr5
por: Signoret, Nathalie, et al.
Publicado: (2000)

Frequency of CCR5 genotypes in HIV-infected patients in Roraima, Brazil
por: Corado, André de Lima Guerra, et al.
Publicado: (2016)

CCR5 Levels and Expression Pattern Correlate with Infectability by Macrophage-tropic HIV-1, In Vitro
por: Wu, Lijun, et al.
Publicado: (1997)

Novel AgoshRNA molecules for silencing of the CCR5 co-receptor for HIV-1 infection
por: Herrera-Carrillo, Elena, et al.
Publicado: (2017)

Escape of HIV-1 from a Small Molecule CCR5 Inhibitor Is Not Associated with a Fitness Loss
por: Anastassopoulou, Cleo G, et al.
Publicado: (2007)

Pharmacophore-Oriented Identification of Potential Leads as CCR5 Inhibitors to Block HIV Cellular Entry
por: Singh, Pooja, et al.
Publicado: (2022)

CCR5 structural plasticity shapes HIV-1 phenotypic properties
por: Colin, Philippe, et al.
Publicado: (2018)

Blockade of chemokine-induced signalling inhibits CCR5-dependent HIV infection in vitro without blocking gp120/CCR5 interaction
por: Grainger, David J, et al.
Publicado: (2005)

Vaginal rings with exposed cores for sustained delivery of the HIV CCR5 inhibitor 5P12-RANTES
por: McBride, John W., et al.
Publicado: (2019)

Human and chicken antibodies to CCR5-ECL1 block mucosal and systemic HIV infection
por: Lopalco, Lucia, et al.
Publicado: (2006)

The role of CCR5 in HIV-associated neurocognitive disorders
por: Riviere-Cazaux, Cecile, et al.
Publicado: (2022)

CCR5/CXCR4 Dual Antagonism for the Improvement of HIV Infection Therapy
por: Grande, Fedora, et al.
Publicado: (2019)

Interleukin 10 Increases CCR5 Expression and HIV Infection in Human Monocytes
por: Sozzani, Silvano, et al.
Publicado: (1998)

Mutant chemokine receptor (CCR-5) and its relevance to HIV infection in Arabs.
por: al-Sheikh, I H, et al.
Publicado: (1999)

Host cell glycosylation selects for infection with CCR5- versus CXCR4-tropic HIV-1
por: Itell, Hannah L., et al.
Publicado: (2023)

Targeting CCR5 as a Component of an HIV-1 Therapeutic Strategy
por: Mohamed, Hager, et al.
Publicado: (2022)

The role of CCR5 in HCV infection
por: Coenen, Martin, et al.
Publicado: (2010)

CCR2/CCR5 inhibitor permits the radiation-induced effector T cell infiltration in pancreatic adenocarcinoma
por: Wang, Jianxin, et al.
Publicado: (2022)

Polymorphisms in CCR5Δ32 and Risk of HIV-1 Infection in the Southeast of Caspian Sea, Iran
por: Heydarifard, Zahra, et al.
Publicado: (2017)

The CCR5-Delta32 Genetic Polymorphism and HIV-1 Infection Susceptibility: a Meta-analysis
por: Ni, Jun, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_r4hgo6um9u0in0phmgr9gpfmfn